Tumor inhibitory properties of anaerobic Corynebacteria.
D000693:Anaerobiosis; D000818:Animals; D000907:Antibodies, Bacterial; D000970:Antineoplastic Agents / Q000302:isolation & purification*; D002283:Carcinoma, Bronchogenic / Q000628:therapy; D002986:Clinical Trials as Topic; D003352:Corynebacterium / Q000032:analysis*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005260:Female; D005354:Fibrosarcoma / Q000517:prevention & control*; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008175:Lung Neoplasms / Q000628:therapy; D008325:Mammary Neoplasms, Experimental / Q000517:prevention & control*; D051379:Mice; D008805:Mice, Inbred A; D008808:Mice, Inbred CBA; D008875:Middle Aged; D009374:Neoplasms, Experimental; D011425:Propionibacterium acnes / Q000032:analysis*; D013601:T-Lymphocytes
D000907:Antibodies, Bacterial; D000970:Antineoplastic Agents; D003520:Cyclophosphamide